MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:MDXG
- CUSIP: N/A
- Web: www.mimedx.com
- Market Cap: $1.55 billion
- Outstanding Shares: 110,871,000
- 50 Day Moving Avg: $14.99
- 200 Day Moving Avg: $11.40
- 52 Week Range: $6.94 - $16.20
Sales & Book Value:
- Trailing P/E Ratio: 106.21
- Foreward P/E Ratio: 37.56
- P/E Growth: 3.33
- Annual Revenue: $264.26 million
- Price / Sales: 6.15
- Book Value: $1.22 per share
- Price / Book: 12.01
- EBIDTA: $29.49 million
- Net Margins: 5.72%
- Return on Equity: 12.25%
- Return on Assets: 8.39%
- Current Ratio: 2.46%
- Quick Ratio: 2.13%
- Average Volume: 1.43 million shs.
- Beta: 1.04
- Short Ratio: 16.18
Frequently Asked Questions for MiMedx Group (NASDAQ:MDXG)
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group announced that its Board of Directors has approved a share buyback plan on Monday, April 10th 2017, which allows the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group, Inc (NASDAQ:MDXG) announced its quarterly earnings results on Friday, April, 28th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.00. The business had revenue of $72.60 million for the quarter, compared to analysts' expectations of $72.60 million. MiMedx Group had a net margin of 5.72% and a return on equity of 12.25%. The firm's revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.04 EPS. View MiMedx Group's Earnings History.
What guidance has MiMedx Group issued on next quarter's earnings?
MiMedx Group updated its FY17 earnings guidance on Friday, April, 28th. The company provided earnings per share guidance of $0.31-0.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.32. The company issued revenue guidance of $303.5-307.0 million, compared to the consensus revenue estimate of $304.53 million.
Where is MiMedx Group's stock going? Where will MiMedx Group's stock price be in 2017?
4 equities research analysts have issued 12 month price targets for MiMedx Group's stock. Their predictions range from $10.00 to $20.00. On average, they expect MiMedx Group's share price to reach $13.25 in the next year. View Analyst Ratings for MiMedx Group.
What are analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "We expect the upcoming top line data from MDXG’s diabetic foot ulcer (DFU) and venous leg ulcer (VLU) multi-center randomized controlled trials (RCTs) to be positive catalysts. MDXG disclosed positive interim results from the VLU RCT during its 3/9/17 investor call. Assuming good final results, we expect the trials to drive growth by prompting more insurers to cover EpiFix and more physicians to use EpiFix." (6/26/2017)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (2/21/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a decrease in short interest in June. As of June 30th, there was short interest totalling 20,263,818 shares, a decrease of 10.9% from the June 15th total of 22,752,219 shares. Based on an average daily trading volume, of 1,353,029 shares, the days-to-cover ratio is currently 15.0 days. Approximately 19.8% of the shares of the company are short sold.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include LivaNova PLC (LIVN), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR) and Invacare Corporation (IVC).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Parker H. Petit Jr., Chairman of the Board, Chief Executive Officer
- William Charles Taylor, President, Chief Operating Officer, Director
- Michael J. Senken, Chief Financial Officer
- Alexandra O. Haden, General Counsel, Secretary
- Charles E. Koob, Director
- Luis A. Aguilar, Independent Director
- Joseph G. Bleser, Independent Director
- J. Terry Dewberry, Independent Director
- Charles R. Evans, Independent Director
Who owns MiMedx Group stock?
MiMedx Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.33%), Summit Creek Advisors LLC (0.33%), Westwood Management Corp IL (0.23%), Acadian Asset Management LLC (0.12%), Strs Ohio (0.06%) and Boston Advisors LLC (0.05%). Company insiders that own MiMedx Group stock include Alexandra O Haden, Charles Robert Evans, Parker H Petit and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.
Who sold MiMedx Group stock? Who is selling MiMedx Group stock?
MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Boston Advisors LLC, Capstone Asset Management Co. and LS Investment Advisors LLC. View Insider Buying and Selling for MiMedx Group.
Who bought MiMedx Group stock? Who is buying MiMedx Group stock?
MiMedx Group's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Strs Ohio, Russell Investments Group Ltd., State of Alaska Department of Revenue, Aperio Group LLC and Louisiana State Employees Retirement System. Company insiders that have bought MiMedx Group stock in the last two years include Alexandra O Haden, Charles Robert Evans and Parker H Petit. View Insider Buying and Selling for MiMedx Group.
How do I buy MiMedx Group stock?
Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MiMedx Group stock can currently be purchased for approximately $14.65.
Consensus Ratings for MiMedx Group (NASDAQ:MDXG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$13.25 (9.56% downside)|
Analysts' Ratings History for MiMedx Group (NASDAQ:MDXG)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/26/2017||Needham & Company LLC||Reiterated Rating||Buy||$15.00 -> $20.00||Medium|
|5/23/2017||First Analysis||Downgrade||Equal Weight -> Underweight||$11.00||High|
|3/3/2017||Piper Jaffray Companies||Initiated Coverage||Overweight -> Overweight||$10.00||N/A|
|6/29/2016||Brean Capital||Reiterated Rating||Buy||N/A|
|4/19/2016||Lake Street Capital||Lower Price Target||Buy||$15.00 -> $12.00||N/A|
|1/13/2016||Canaccord Genuity||Reiterated Rating||Buy||$12.00||N/A|
|10/30/2015||Northland Securities||Upgrade||Market Perform -> Outperform||$10.00||N/A|
Earnings History for MiMedx Group (NASDAQ:MDXG)Earnings History by Quarter for MiMedx Group (NASDAQ MDXG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2017||Q1 2017||$0.07||$0.07||$72.60 million||$72.60 million||View||N/A|
|2/23/2017||Q416||$0.08||$0.05||$71.13 million||$69.90 million||View||Listen|
|10/27/2016||Q316||$0.06||$0.06||$63.18 million||$64.40 million||View||Listen|
|7/26/2016||Q216||$0.07||$0.05||$56.49 million||$57.00 million||View||Listen|
|4/25/2016||Q116||$0.05||$0.04||$54.05 million||$53.40 million||View||Listen|
|2/23/2016||Q415||$0.06||$0.12||$51.84 million||$51.80 million||View||Listen|
|10/29/2015||Q315||$0.06||$0.06||$48.61 million||$49.00 million||View||Listen|
|7/30/2015||Q215||$0.04||$0.05||$45.03 million||$45.68 million||View||Listen|
|2/26/2015||Q414||$0.03||$0.03||$38.15 million||$39.60 million||View||Listen|
|10/30/2014||Q314||$0.02||$0.03||$33.50 million||$33.50 million||View||Listen|
|4/25/2014||Q114||($0.02)||($0.01)||$19.09 million||$19.60 million||View||Listen|
|2/26/2014||Q4||($0.01)||($0.04)||$18.31 million||$18.00 million||View||Listen|
|7/31/2013||Q2 2013||($0.01)||($0.01)||$12.94 million||$13.52 million||View||Listen|
|5/1/2013||Q1 2013||($0.02)||($0.02)||$11.34 million||$11.56 million||View||Listen|
Earnings Estimates for MiMedx Group (NASDAQ:MDXG)
2017 EPS Consensus Estimate: $0.26
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for MiMedx Group (NASDAQ:MDXG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MiMedx Group (NASDAQ:MDXG)
Insider Ownership Percentage: 12.40%Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Institutional Ownership Percentage: 55.75%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/14/2017||William Charles Taylor||Insider||Sell||80,000||$14.52||$1,161,600.00|| |
|5/25/2017||William Charles Taylor||Insider||Sell||26,571||$13.74||$365,085.54|| |
|4/27/2017||William Charles Taylor||Insider||Sell||26,000||$11.40||$296,400.00|| |
|9/6/2016||William Charles Taylor||Insider||Sell||20,400||$7.55||$154,020.00|| |
|8/1/2016||William Charles Taylor||Insider||Sell||29,112||$7.55||$219,795.60|| |
|6/16/2016||William Charles Taylor||COO||Sell||24,333||$7.52||$182,984.16|| |
|5/20/2016||Parker H Petit||CEO||Buy||20,000||$6.99||$139,800.00|| |
|5/17/2016||Parker H Petit||CEO||Buy||30,000||$6.82||$204,600.00|| |
|5/13/2016||Parker H Petit||CEO||Buy||40,000||$6.75||$270,000.00|| |
|5/12/2016||Parker H Petit||CEO||Buy||50,000||$6.74||$337,000.00|| |
|11/13/2015||Charles Robert Evans||Director||Buy||10,000||$7.84||$78,400.00|| |
|11/10/2015||Parker H Petit||CEO||Buy||131,925||$7.58||$999,991.50|| |
|10/30/2015||Alexandra O. Haden||General Counsel||Buy||4,150||$7.92||$32,868.00|| |
|5/28/2015||Larry W Papasan||Director||Sell||5,958||$10.09||$60,116.22|| |
|5/18/2015||William Charles Taylor||COO||Sell||150,000||$10.01||$1,501,500.00|| |
|10/31/2014||William Charles Taylor||COO||Sell||150,000||$10.01||$1,501,500.00|| |
|7/1/2014||William Charles Taylor||COO||Sell||150,000||$7.50||$1,125,000.00|| |
|1/17/2014||Parker Petit||CEO||Sell||150,000||$8.28||$1,242,000.00|| |
|8/28/2013||William Charles Taylor||COO||Sell||9,800||$6.15||$60,270.00|| |
|8/7/2013||William Charles Taylor||COO||Sell||183,765||$6.21||$1,141,180.65|| |
|5/16/2013||Steve Gorlin||Director||Sell||30,000||$6.46||$193,800.00|| |
Headline Trends for MiMedx Group (NASDAQ:MDXG)
Latest Headlines for MiMedx Group (NASDAQ:MDXG)
|MiMedx Group, Inc (MDXG) Given Average Rating of "Hold" by Brokerages|
www.americanbankingnews.com - July 17 at 12:33 PM
|MiMedx Group, Inc (NASDAQ:MDXG) Short Interest Down 10.9% in June|
www.americanbankingnews.com - July 15 at 7:26 AM
|MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers - TheStreet.com|
www.thestreet.com - July 15 at 6:24 AM
|MiMedx Group (MDXG) Prelim. Q2 Revenue Beats - StreetInsider.com|
www.streetinsider.com - July 15 at 6:24 AM
|MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : July 14, 2017|
finance.yahoo.com - July 15 at 6:24 AM
|MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers|
finance.yahoo.com - July 15 at 6:24 AM
|After-Hours Stock Movers 7/13: (CLIR) (BLFS) (AFMD) Higher; (ATEN) (CYBR) (FEYE) Lower (more...)|
www.streetinsider.com - July 14 at 6:24 AM
|MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range|
www.bizjournals.com - July 14 at 6:24 AM
|/C O R R E C T I O N -- MiMedx Group, Inc./|
finance.yahoo.com - July 14 at 6:24 AM
|ETFs with exposure to MiMedx Group, Inc. : July 11, 2017|
finance.yahoo.com - July 12 at 3:24 AM
|MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down - PR Newswire (press release)|
www.prnewswire.com - July 6 at 2:25 AM
|BidaskClub Lowers MiMedx Group, Inc (MDXG) to Hold|
www.americanbankingnews.com - July 5 at 7:28 PM
|MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down|
finance.yahoo.com - July 5 at 4:21 PM
|ETFs with exposure to MiMedx Group, Inc. : June 30, 2017|
finance.yahoo.com - July 1 at 1:03 AM
|MiMedx Group, Inc (MDXG) Earns Buy Rating from Needham & Company LLC|
www.americanbankingnews.com - June 26 at 12:16 PM
|MiMedx Group (MDXG) PT Raised to $20 at Needham & Company; 'We Expect Wound RCTs to Drive Increased EpiFix ... - StreetInsider.com|
www.streetinsider.com - June 26 at 9:10 AM
|MiMedx Group, Inc (MDXG) Rating Increased to Buy at BidaskClub|
www.americanbankingnews.com - June 24 at 5:32 PM
|Medical Equipment Stock Performance Review -- MiMedx, Stryker, Zimmer Biomet, and ResMed|
www.prnewswire.com - June 22 at 8:45 AM
|MiMedx Group, Inc (MDXG) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - June 20 at 12:46 PM
|ETFs with exposure to MiMedx Group, Inc. : June 19, 2017|
finance.yahoo.com - June 19 at 5:31 PM
|William Charles Taylor Sells 80,000 Shares of MiMedx Group, Inc (MDXG) Stock|
www.americanbankingnews.com - June 16 at 10:16 PM
|MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017|
finance.yahoo.com - June 16 at 7:26 PM
|MiMedx Group (MDXG): Scientific & Clinical Review Highlights ... - StreetInsider.com|
www.streetinsider.com - June 16 at 7:39 AM
|Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics|
finance.yahoo.com - June 16 at 7:39 AM
|MiMedx Group (MDXG) Says Amniofix Data Presented at ASCRS|
www.streetinsider.com - June 13 at 11:38 PM
|MiMedx Group (MDXG) Says Amniofix Data Presented at ASCRS - StreetInsider.com|
www.streetinsider.com - June 13 at 6:37 PM
|MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS Meeting|
finance.yahoo.com - June 13 at 6:37 PM
|MiMedx Group Inc (MDXG) Short Interest Up 6.0% in May|
www.americanbankingnews.com - June 11 at 12:46 PM
|MiMedx Group (MDXG) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow|
seekingalpha.com - June 8 at 7:25 PM
|Analyzing Varian Medical Systems (VAR) and MiMedx Group (MDXG)|
www.americanbankingnews.com - June 6 at 2:06 PM
|MiMedx to Present at the Jefferies 2017 Global Healthcare Conference|
finance.yahoo.com - June 1 at 9:28 AM
|William Charles Taylor Sells 26,571 Shares of MiMedx Group Inc (MDXG) Stock|
www.americanbankingnews.com - May 30 at 7:41 PM
|First Analysis Downgrades MiMedx Group Inc (MDXG) to Underweight|
www.americanbankingnews.com - May 28 at 12:32 AM
|MiMedx Group Inc (MDXG) Short Interest Down 18.1% in May|
www.americanbankingnews.com - May 27 at 7:06 AM
|MiMedx Group Inc (MDXG) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - May 26 at 1:31 PM
|MiMedx To Attend The 14th Annual Craig-Hallum Institutional Investor Conference|
finance.yahoo.com - May 19 at 11:01 AM
|MiMedx Group Inc (MDXG) Short Interest Down 10.7% in April|
www.americanbankingnews.com - May 12 at 7:08 AM
|MiMedx Group (MDXG) Announces EpiFix Coverage From Kaiser Permanente - StreetInsider.com|
www.streetinsider.com - May 4 at 6:35 PM
|MiMedx Group (MDXG) Announces EpiFix Coverage From Kaiser Permanente|
www.streetinsider.com - May 4 at 11:43 AM
|MiMedx EpiFix® Receives Coverage From Kaiser Permanente|
finance.yahoo.com - May 4 at 11:43 AM
|MiMedx Group (MDXG) Earns Daily Coverage Optimism Rating of 0.51|
www.americanbankingnews.com - May 2 at 10:00 PM
|First Analysis Comments on MiMedx Group Inc's Q1 2018 Earnings (MDXG)|
www.americanbankingnews.com - May 2 at 2:50 PM
|MiMedx Group, Inc.: Leads amongst peers with strong fundamentals|
finance.yahoo.com - May 1 at 5:29 PM
|MiMedx Group Inc (MDXG) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 1 at 4:42 PM
|MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.|
finance.yahoo.com - May 1 at 12:42 PM
|Edited Transcript of MDXG earnings conference call or presentation 28-Apr-17 2:30pm GMT|
finance.yahoo.com - May 1 at 12:42 PM
|MiMedx Group Inc (MDXG) Expected to Announce Quarterly Sales of $70.64 Million|
www.americanbankingnews.com - April 30 at 7:54 AM
|Positive News Coverage Very Likely to Affect MiMedx Group (MDXG) Stock Price|
www.americanbankingnews.com - April 29 at 6:11 PM
|MiMedx Group Inc (MDXG) Issues Quarterly Earnings Results|
www.americanbankingnews.com - April 29 at 1:14 AM
|William Charles Taylor Sells 26,000 Shares of MiMedx Group Inc (MDXG) Stock|
www.americanbankingnews.com - April 29 at 1:10 AM
MiMedx Group (MDXG) Chart for Wednesday, July, 26, 2017